-
公开(公告)号：US11911379B2
公开(公告)日：2024-02-27
申请号：US17570928
申请日：2022-01-07
Applicant: ADS Therapeutics LLC
Inventor： Jinsong Ni , Rong Yang
IPC: A61K31/496 , A61K9/00 , A61K9/08 , A61K9/107 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/416 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/675 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/40 , A61P27/02 , A61P27/06
CPC classification number: A61K31/496 , A61K9/0048 , A61K9/0051 , A61K9/08 , A61K9/107 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/416 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/675 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/186 , A61K47/26 , A61K47/36 , A61K47/40 , A61P27/02 , A61P27/06
Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.
-
公开(公告)号：US12214049B2
公开(公告)日：2025-02-04
申请号：US17065901
申请日：2020-10-08
Applicant: ADS Therapeutics LLC
Inventor： Jinsong Ni , Rong Yang
IPC: A61K39/395 , A61K9/00 , A61K9/08 , A61K31/496 , A61K47/64 , A61K47/68 , C07K16/00 , C07K16/22 , A61K47/46
Abstract: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.
-
公开(公告)号：US12070501B1
公开(公告)日：2024-08-27
申请号：US17976660
申请日：2022-10-28
Applicant: ADS Therapeutics LLC
Inventor： Jinsong Ni , Van Dinh , Rong Yang
CPC classification number: A61K47/14 , A61K9/0048 , A61K31/46 , A61K47/06 , A61P27/10
Abstract: A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.
-
4.发明公开公开(公告)号：US20240238279A1
公开(公告)日：2024-07-18
申请号：US18416302
申请日：2024-01-18
Applicant: ADS Therapeutics LLC
Inventor： Jinsong Ni , Rong Yang
IPC: A61K31/496 , A61K9/00 , A61K9/08 , A61K9/107 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/416 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/675 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/40 , A61P27/02 , A61P27/06
CPC classification number: A61K31/496 , A61K9/0048 , A61K9/0051 , A61K9/08 , A61K9/107 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/416 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/675 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/186 , A61K47/26 , A61K47/36 , A61K47/40 , A61P27/02 , A61P27/06
Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.
-
公开(公告)号：US20230355594A1
公开(公告)日：2023-11-09
申请号：US18029323
申请日：2021-10-08
Applicant: ADS THERAPEUTICS LLC
Inventor： Jinsong NI , Rong YANG
IPC: A61K31/439 , A61K47/06 , A61P27/10 , A61K9/00
CPC classification number: A61K31/439 , A61K47/06 , A61P27/10 , A61K9/0048
Abstract: A topical ophthalmological composition includes a therapeutically effective amount of a muscarinic receptor antagonist as an active pharmaceutical ingredient; and a semifluorinated alkane, as a liquid vehicle. The topical ophthalmological composition treats an ocular disease.
-
Patent Agency Ranking
公开(公告)号：US20220362282A1
公开(公告)日：2022-11-17
申请号：US17624516
申请日：2020-06-15
Applicant: ADS THERAPEUTICS LLC
Inventor： Jinsong NI , Rong YANG
IPC: A61K31/724 , A61K47/02 , A61P27/04
Abstract: A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.
-
公开(公告)号：US11166977B2
公开(公告)日：2021-11-09
申请号：US16901721
申请日：2020-06-15
Applicant: ADS THERAPEUTICS LLC
Inventor： Jinsong Ni , Rong Yang
IPC: A61K31/724 , A61P27/02 , A61K9/00 , A61P27/04 , A61K47/26 , A61K47/12 , A61K47/38 , A61K47/02 , A61K47/44 , A61K47/10 , A61K47/18 , A61K9/06 , A61K9/08
Abstract: A method for treating a meibomian gland dysfunction of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of a cyclic polysaccharide. A steroidal-androgen-free composition includes a cyclic polysaccharide as an active pharmaceutical ingredient for treating a meibomian gland dysfunction of an affected eye.
-
8.发明授权公开(公告)号：US12156873B2
公开(公告)日：2024-12-03
申请号：US17057886
申请日：2019-05-23
Applicant: ADS Therapeutics LLC
Inventor： Scott Whitcup , Rong Yang , Jinsong Ni
IPC: A61K31/498 , A61K9/00 , A61K9/06 , A61K9/08 , A61K9/107 , A61K31/496 , A61K47/26 , A61K47/34 , A61K47/36 , A61P27/02
Abstract: A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an α adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating α adrenergic receptor of the patient with an agonist of the receptor.
-
公开(公告)号：US20220125783A1
公开(公告)日：2022-04-28
申请号：US17570928
申请日：2022-01-07
Applicant: ADS Therapeutics LLC
Inventor： Jinsong Ni , Rong Yang
IPC: A61K31/496 , A61K9/00 , A61P27/02 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/416 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/675 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/40 , A61P27/06 , A61K9/08 , A61K9/107 , A61K45/06
Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.
-
公开(公告)号：US20210030889A1
公开(公告)日：2021-02-04
申请号：US17065901
申请日：2020-10-08
Applicant: ADS Therapeutics LLC
Inventor： Jinsong NI , Rong YANG
IPC: A61K47/68 , C07K16/22 , A61K9/08 , A61K9/00 , C07K16/00 , A61K31/496 , A61K39/395
Abstract: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.015 seconds)
